Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland

BACKGROUND: Injectable disease-modifying drugs (DMDs) reduce the number of relapses and delay disability progression in patients with relapsing–remitting multiple sclerosis (RRMS). Regular self-injection can be stressful and impeded by MS symptoms. Auto-injection devices can simplify self-injection,...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Arcy, Caroline, Thomas, Del, Stoneman, Dee, Parkes, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269318/
https://www.ncbi.nlm.nih.gov/pubmed/22298944
http://dx.doi.org/10.2147/PPA.S26250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269318/
https://www.ncbi.nlm.nih.gov/pubmed/22298944
http://dx.doi.org/10.2147/PPA.S26250

Ejemplares similares